Future studies may be able to incorporate pharmacist-led intensification of preventive care in the context of expanded indications for SGLT-2 inhibitors to primary prevention patients without diabetes, given the low risk of hypoglycemia with these agents owing to their mechanisms of action (45). Here, SLC5A2 is linked to diabetes mellitus.